Ocuphire Pharma
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-02-01
- Employees
- 14
- Market Cap
- $31.9M
- Website
- http://www.ocuphire.com
- Introduction
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
Phase 2
Completed
- Conditions
- Disturbance; Vision, LossDecrease in Night Vision
- Interventions
- Drug: Phentolamine Mesylate Ophthalmic Solution 1%Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04004507
- Locations
- 🇺🇸
Ophthalmic Consultants of Long Island, NY, Lynbrook, New York, United States
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma
Phase 2
Completed
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Drug: Phentolamine Mesylate Ophthalmic Solution 1%
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03960866
- Locations
- 🇺🇸
Clayton Eye Clinical Research, Morrow, Georgia, United States
🇺🇸Abrams Eye Center, Cleveland, Ohio, United States
🇺🇸University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
Phase 2
Completed
- Conditions
- Decrease in Night VisionDisturbance; Vision, LossNight Vision Complaints
- Interventions
- Drug: Phentolamine Mesylate Ophthalmic Solution 1.0%Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Drug: Phentolamine Mesylate Ophthalmic Solution 0.5%
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01703559
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath